Format

Send to

Choose Destination
Cancer Lett. 2018 May 1;421:59-62. doi: 10.1016/j.canlet.2018.02.003. Epub 2018 Feb 6.

Out of the darkness and into the light: New strategies for improving treatments for locally advanced non-small cell lung cancer.

Author information

1
School of Medicine and Life Sciences, University of Jinan Shandong Academy of Medical Sciences, Jinan, Shandong, China; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong, 250117, China.
2
Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Zhen Hai Road 55, Xiamen, Fujian, 361003, China.
3
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
4
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA; Division of Epidemiology, Human Genetics and Environmental Sciences, The University of Texas School of Public Health at Houston, 1200 Hermann Pressler St., Houston, TX, 77030, USA.
5
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong, 250117, China.
6
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong, 250117, China. Electronic address: jinbo.yue@gmail.com.

Abstract

The standard treatment for locally advanced non-small cell lung cancer (LA NSCLC) includes surgery, radiotherapy, chemotherapy, or some combination of these modalities. Many clinical trials have been conducted in attempts to intensify treatment for LA NSCLC, but with little improvement. A therapeutic plateau had been reached, with no major progress in extending survival for patients with this disease. However, several recent trials of newer targeted therapies and immunotherapies may shed new light on potential therapeutic breakthroughs. The potential benefits from new targeted therapies and immunotherapies in combination with other forms of therapy for LA NSCLC are sufficiently striking as to change current treatment paradigms. Trials of these agents are moving forward from patients with advanced disease to those with earlier stage disease, and from palliative intent to curative intent, which may well revolutionize treatment strategies that have been considered standard over the past several decades. Future studies are needed to explore the role of targeted therapies and immunotherapies in combination with existing therapies for earlier stage disease and for frontline treatment, either as concurrent or perhaps neoadjuvant or adjuvant approaches.

KEYWORDS:

Immunotherapies; Non-small cell lung cancer; Radiotherapy; Targeted therapies

PMID:
29425685
DOI:
10.1016/j.canlet.2018.02.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center